🦊/Investors

Bay City CapitalFull Portfolio

84 tracked investments · listed companies and verified rows first

Damora TherapeuticsNASDAQ: DMRANov 2025

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Board seatCarl Goldfischer· per SEC Form D

Co-investorsAccess BiotechnologyBAM ElevateCommodore CapitalEIR VenturesForbionJanus Henderson Investors+6 more

ImaraNASDAQ: ELVNMar 2019acquired by Enliven Therapeutics · Feb 2023

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Board seatCarl Goldfischer· per SEC Form D

Co-investorsNew Enterprise Associates (NEA)RA CapitalArix BioscienceOrbiMed

AntriaBioNASDAQ: RZLT

Rezolute develops ersodetug, an intravenously administered monoclonal antibody targeting the insulin receptor to treat hypoglycemia caused by hyperinsulinism, with late-stage clinical programs in congenital hyperinsulinism and tumor-related hyperinsulinism.

BiotechLouisville, US

Sankaram Mantripragada(Executive Officer)Nevan Charles Elam(Executive Officer, Director)Morgan Lynn Fields(Executive Officer)Brian Roberts(Chief Medical Officer)Daron Evans(Chief Financial Officer)Sunil Karnawat(Chief Commercial Officer)

Enliven Therapeuticsenliventherapeutics.cominNASDAQ: ELVN

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5AM VenturesOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersNew Enterprise Associates (NEA)+1 more

Gossamer Biogossamerbio.comin𝕏NASDAQ: GOSS

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

Faheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSheila Gujrathi, MD(Founder)inBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Co-investorsARCH Venture PartnersEcoR1 CapitalFoothill VenturesNew Enterprise Associates (NEA)Samsara BioCapitalOmega Funds

Madrigalmadrigalpharma.comin𝕏NASDAQ: MDGL

Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).

BiotechHealthtechMedical DevicesConshohocken, US

Rebecca Taub(Founder and Director)inMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCarole Huntsman(Executive Vice President and Chief Commercial Officer)in

Co-investorsAvoro Capital AdvisorsForesite Capital

NextCurenextcure.comNASDAQ: NXTC

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Co-investorsCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+4 more

Ptcbioptcbio.comin𝕏NASDAQ: PTCT

PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options.

BiotechHealthtechSouth Plainfield, US

Stuart W. Peltz(Executive Officer, Director)Allan S. Jacobson(Director)inAllan Jacobson(Director)inMark E. Boulding(Executive Officer)inChristine Utter(Executive Officer)inMarcio Souza(Executive Officer)in

Co-investorsLongwood Fund

Twist Biosciencetwistbioscience.comin𝕏NASDAQ: TWST

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.

BiotechDeep TechSemiconductorsSouth San Francisco, US

William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily M. Leproust(Chief Executive Officer and Chair of the Board)inPatrick Finn(President and Chief Operating Officer)inAdam Laponis(Chief Financial Officer)in

Co-investors+ND Capital3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyBlack Opal VenturesDentsu Ventures+8 more

Xilio Therapeuticsxiliotx.cominNASDAQ: XLO

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Co-investorsBain Capital Life SciencesF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+9 more

EnteroMedicsinMay 2017

HealthtechSt Paul, US

Dan W Gladney(Executive Officer, Director)Scott P Youngstrom(Executive Officer)Rajesh Nihalani(Executive Officer)Peter M DeLange(Executive Officer)inPaul F Hickey(Executive Officer)inNaqeeb A Ansari(Executive Officer)

Board seatCarl Goldfischer· per SEC Form D

Civitas Therapeuticscivitastherapeutics.comSeries B · Aug 2014 · $38M

BiotechChelsea, US

RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in

BoardROB HOPFNER(Director)in

Co-investorsCanaan PartnersSofinnova VenturesLongitude CapitalOrbiMedRA Capital

Cymabaycymabay.comin𝕏Aug 2015

Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.

BiotechHealthtechMedical DevicesNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in

Co-investorsAvoro Capital AdvisorsForesite CapitalVantagePoint Capital PartnersAbingworth

Dermiradermira.com

HealthtechMenlo Park, US

Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)

BoardFred Craves(Director)in

Co-investorsAisling CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more

Epocratesepocrates.comin𝕏

David Minkinin

Co-investorsMillennium Technology Value PartnersThreshold Ventures

Gritstone Oncologygritstoneoncology.comin

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.

BiotechDeep TechHealthtechSan Carlos, US

Wayne(CEO)Rachel(VP of Operations)

Co-investorsGV (Google Ventures)LAVLilly Asia Ventures

Interleukin Geneticsin

BiotechWatham, US

Kenneth Kornman(Executive Officer, Director)inStephen DiPalma(Executive Officer)

BoardJoseph Landstra(Director)Lionel Carnot(Director)Dayton Misfeldt(Director)James Weaver(Director)

Iterum Therapeuticsiterumtx.com

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

Michael W. Dunne(Executive Officer, Promoter)inCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Co-investorsCanaan PartnersSofinnova VenturesAdvent Life SciencesFrazier Life SciencesSofinnova Venture Partners

Kbpbiokbpbio.com

KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.

Biotech

Co-investorsHM Venture Partners

Kezar Life Scienceskezarlifesciences.comin𝕏

Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.

BiotechSouth San Francisco, US

John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)

BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)

Co-investorsChiesi VenturesPappas CapitalSolasta VenturesEcoR1 CapitalQiming Venture Partners

Nevronevro.comin

Nevro develops spinal cord stimulation systems for pain management, offering the Senza Trial Stimulator with high-frequency therapy options and wireless capability for patient trials and treatment.

AI & Machine LearningDigital HealthHealthtechMedical DevicesRedwood City, US

Co-investorsNew Enterprise Associates (NEA)

Nextwavepharmanextwavepharma.comacquired by Tris Pharma

Medical DevicesNew Jersey, US

Co-investorsF-Prime CapitalSofinnova Ventures

Oculisoculis.comin

Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.

BiotechHealthtechMedical DevicesBoston, CH

Riad Sherif(Chief Executive Officer)in

Co-investorsBrunnur Ventures GPVI PartnersBVCFPivotal Life Sciences

Senomyxfirmenich.comin𝕏Acquired

Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.

ConsumerHealthtechNew MaterialsGeneva, CH

Gilbert Ghostinein

Co-investorsProspect Venture PartnersRho Ventures

Tetraphase PharmaceuticalsinJan 2020acquired by La Jolla Pharmaceutical Company · Jul 2020 · $43M

Tetraphase Pharmaceuticals was a Watertown, MA biopharmaceutical company developing novel tetracycline antibiotics, including its lead drug Xerava (eravacycline) for multidrug-resistant bacterial infections.

BiotechWatertown, US

Guy Macdonald(Director)inLarry Edwards(Executive Officer, Director)inMaria Stahl(Executive Officer)inChristopher Watt(Executive Officer)

BoardL. Patrick Gage(Director)Keith Maher(Director)

Co-investorsF-Prime CapitalExcel Venture ManagementFlagship VenturesMediphase Venture Partners

Tria Beautytriabeauty.comin

Tria develops handheld laser devices for at-home hair removal and skincare, using laser technology similar to that used in professional clinics.

ConsumerDirect to ConsumerHardwareHealthtechWellness & FitnessDublin, US

TOBIN C. ISLAND(Executive Officer)inKEVIN J. APPELBAUM(Executive Officer, Director)inDEREK YUNG(Executive Officer)inDANIKA HARRISON(Executive Officer)inJIYOUNG CHOI(Executive Officer)CHARLES BRACHER(Director)in

Co-investorsAisling CapitalIncubic Management LLCVivo Capital

Vivaldi Biosciencesvivaldibiosciences.com

Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.

BiotechHealthtechMedical DevicesFort Collins, US

Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)

Co-investorsNGN Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Sidecar TherapeuticsSynGenAccriva DiagnosticsAciexAmerifit NutritionAqua Bounty TechAragon SurgicalAscendancy HealthcareBiorenBioSeekBlade TherapeuticsCadence PharmaceuticalsCalypso MedicalChemdexConatus PharmaCydanEos BiotechnologyEpizymeEpoch BiosciencesGenturaDxHyperion TherapeuticsIdev Technologies IncIncyte GenomicsIngenuity SystemsIntarcia TherapeuticsIon Torrent SystemsItamar MedicalLexLjl BiosystemsMap PharmaceuticalsMaxia PharmaMedarexMenlo TherapeuticsMerus BiopharmaNeoRxNupathe PharmaOculex PharmaceuticalsOmegatechOmiciaPanomicsPathway DxPharmakeaPharmanexPharmionPresidio PharmaProtez PharmaRadiant MedicalReliant PharmaceuticalsSembiosys GeneticsSymyx TechnologiesSynchronicity PharmaSyntonix PharmaSyrrxViractaVnus Medical TechVtesse IncXeris Pharmaceuticals

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.